课题基金 / 基金详情

Institute of Human Virology Annual Meeting 2016-2021

Institute of Human Virology Annual Meeting 2016-2021
人类病毒学研究所2016-2021年年会
批准号:
9981608
负责人:
ROBERT C GALLO
金额:
$3.0万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-18 至 2024-08-31

项目摘要

项目成果

ROBERT C GALLO的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 人类病毒学研究所年度国际会议在国家癌症研究所开幕 20世纪70年代中期,汇聚了世界上最顶尖的艾滋病毒/艾滋病生物学专家,特别是 基础和疫苗科学以及新的治疗和预防方法。它的五个具体目标 会议是在选定的项目主题内传播最新的研究成果;批判性的 评估新发现对未来研究方向的影响;提供论坛讨论当前 和新出现的问题;确定、支持和建设下一代艾滋病研究人员;以及增加 妇女、少数族裔和其他传统上在科学界代表性较低的个人的参与。 2013年,会议移至俄罗斯联邦莫斯科,并与莫斯科中心共同主办 用于艾滋病毒治疗和预防。这一地点的重大变化认识到了病毒的重要性 在俄罗斯联邦、欧洲和亚洲防治包括艾滋病毒/艾滋病在内的各种疾病,并开辟了新的途径 在人类病毒性疾病的基础研究、诊断、预防和治疗方面的合作 地理中心。该活动于2014年重返巴尔的摩,发扬了深度科学的传统 处于新发现的前沿,并在2015年提供了关于病毒潜伏机制和最近的 了解艾滋病毒治愈的障碍方面的进展。去年的会议还包括一次特别会议 关于全球病毒威胁:将基础科学转化为公共卫生实践,同时还继续关注 结构生物学、免疫学和疫苗,以及关于艾滋病毒共感染/共病的讨论 扩大到包括丙型肝炎和癌症。会议会议通常通过以下方式组织 不同的观点和不同种族的参与者,并穿插着专门设计的讲座 为讨论引入新的学科。会议成果与更广泛的科学界共享 通过在会议材料和网上发布所有演讲者和海报摘要。2016年,18日 一年一度的国际会议定于9月19日至22日在马里兰州巴尔的摩举行,有400人参加 预期中,包括重要的NIH代表。专题会议将包括:在 临床病毒学;免疫学和免疫发病机制;病毒结构和生物学;艾滋病毒治疗 研究;疫苗学进展;淋巴瘤和癌症的感染剂;以及全球最新进展。 海报将在为期4天的会议期间张贴,晚上的活动旨在 参与者与合作者,建立新的科学伙伴关系,并培养下一代艾滋病毒/艾滋病人 由年轻的研究人员在讲台上发表精选摘要。按照传统,一个 奖学金计划将为妇女、少数族裔和其他代表性较低的人群提供 有机会以很少的费用或免费参与。
英文摘要
PROJECT SUMMARY The Annual International Meeting of the Institute of Human Virology began at the National Cancer Institute in the mid-1970s and brings together the world's foremost experts on the biology of HIV/AIDS, particularly on basic and vaccine science and new treatment and prevention approaches. The five specific aims of this conference are to disseminate the most current research findings within the selected program topics; critically assess the impact of new findings on future directions for research; provide a forum for discussion of current and emerging issues; identify, support, and build the next generation AIDS researcher; and increase participation by women, ethnic/racial minorities, and other individuals traditionally underrepresented in science. In 2013, the meeting was moved to Moscow, Russian Federation and co-sponsored with the Moscow Center for HIV Treatment and Prevention. This significant change of venue recognized the importance of viral diseases, including HIV/AIDS, in the Russian Federation, Europe, and Asia, and opened up new avenues of collaboration in basic research, diagnosis, prevention, and treatment of human viral diseases among these geographic centers. The event returned to Baltimore in 2014 carrying forth the tradition of in-depth science at the cutting edge of new discovery, and in 2015 offered sessions on mechanisms of viral latency and recent advances in understanding the barriers to an HIV cure. Last year's meeting also included a special session on global virus threats: translating basic science to public health practice, while focus also continued on structural biology, immunology, and vaccines, and discussions on HIV co-infections/co-morbidities were expanded to included hepatitis C as well as cancer. Meeting sessions are customarily organized with divergent perspectives and ethnically diverse participants and are interspersed with special lectures designed to introduce new disciplines to discussions. Conference results are shared with the broader scientific community through publication of all speaker and poster abstracts in meeting materials and online. In 2016, the 18th Annual International Meeting is scheduled for Sep 19-22 in Baltimore, MD, with 400 participants anticipated, including significant NIH representation. Thematic sessions will include: Advances in Clinical Virology; Immunology and Immunopathogenesis; Viral Structure and Biology; HIV Cure Research; Progress in Vaccinology; Infectious Agents in Lymphoma and Cancer; and a Global Update. Posters will be displayed throughout the 4-day meeting, with evening activities designed to engage participants with collaborators, build new scientific partnerships, and foster the next generation of HIV/AIDS researcher with podium presentation of selected abstracts by young investigators. As is the tradition, a scholarship initiative will offer women, minorities, and other typically under-represented populations with the opportunity to participate for very little or no cost.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Durable Antibody Mediated Protection Against HIV
  • 批准号:
    9141189
  • 项目类别:
  • 资助金额:
    $321.54万
  • 财政年份:
    2016
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
Admin-Core A
  • 批准号:
    9141190
  • 项目类别:
  • 资助金额:
    $21.77万
  • 财政年份:
    2016
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
FLSC Combined with Tat Toxoid as an HIV Prophylactic Vaccine
  • 批准号:
    7854606
  • 项目类别:
  • 资助金额:
    $47.83万
  • 财政年份:
    2009
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
FLSC Combined with Tat Toxoid as an HIV Prophylactic Vaccine
  • 批准号:
    8134640
  • 项目类别:
  • 资助金额:
    $13.57万
  • 财政年份:
    2009
  • 负责人:
    ROBERT C GALLO
  • 依托单位:
海外基金